|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1997-12-2
|
|
pubmed:abstractText |
To determine the maximum-tolerated dose (MTD) of all-trans-retinoic acid (ATRA) administered on an intermittent oral schedule with interferon-alpha2a (IFN-alpha2a) in children with refractory cancer, and whether the marked reduction in plasma ATRA concentrations observed with chronic daily oral dosing could be circumvented with an intermittent dosing schedule.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3330-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9363862-Adolescent,
pubmed-meshheading:9363862-Adult,
pubmed-meshheading:9363862-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9363862-Area Under Curve,
pubmed-meshheading:9363862-Child,
pubmed-meshheading:9363862-Chromatography, High Pressure Liquid,
pubmed-meshheading:9363862-Drug Administration Schedule,
pubmed-meshheading:9363862-Female,
pubmed-meshheading:9363862-Humans,
pubmed-meshheading:9363862-Interferon-alpha,
pubmed-meshheading:9363862-Male,
pubmed-meshheading:9363862-Neoplasms,
pubmed-meshheading:9363862-Recombinant Proteins,
pubmed-meshheading:9363862-Tretinoin,
pubmed-meshheading:9363862-Wilms Tumor
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer.
|
|
pubmed:affiliation |
Pediatric Branch, National Cancer Institute, Bethesda, MD 20892, USA. adamsonp@pbmac.nci.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase I
|
